Perplexity AI vs CoreWeave: employee equity compared
Secondary market prices, valuation trajectory, equity structure, and liquidity outlook for employees choosing between Perplexity AI and CoreWeave.
Perplexity AI
AI-native answer engine and emerging consumer search alternative to Google.
IPO plausible 2027–2029 if growth trajectory holds. Liquidity may come via tender offer or strategic acquisition before listing.
Consumer AI with viral growth; ISO/NSO options; small team = outsized equity per person
CoreWeave
Specialised GPU cloud provider purpose-built for AI/ML training and inference — 45,000+ NVIDIA H100s available on-demand.
IPO plausible 2027–2029 if growth trajectory holds. Liquidity may come via tender offer or strategic acquisition before listing.
Sticky enterprise ARR; RSU (no exercise cost); IPO imminent when ARR > $1B
Key differences for employees
Equity structure
Perplexity AI grants ISO/NSO with strike prices ranging from $60–$85 depending on your grant year. CoreWeave grants RSU — no exercise cost.
Secondary market premium
The secondary market is pricing Perplexity AI at a +0% premium over its last primary round ($22.6B → $22.6B). CoreWeave trades at +3% over its last round ($19B → $19.6B). A higher secondary premium signals stronger investor demand and potentially better near-term liquidity for employees looking to sell.
Revenue and growth
Perplexity AI runs at $0.5B ARR, growing +250% YoY (very fast). CoreWeave runs at $2B ARR, growing +150% YoY (very fast). Revenue growth rate matters for equity because it drives the peer-multiple valuation — the method most correlated with exit multiples.
Liquidity timeline
Perplexity AI: IPO plausible 2027–2029 if growth trajectory holds. Liquidity may come via tender offer or strategic acquisition before listing.
CoreWeave: IPO plausible 2027–2029 if growth trajectory holds. Liquidity may come via tender offer or strategic acquisition before listing.
Calculate your specific grant
Enter your actual shares, equity type, and strike price. PrivatePulse calculates your personal equity value at both companies using 4 independent methods.